Loading...
•
Jun 30, 2025
Ekso Bionics Q2 2025 Earnings Report
Faced revenue decline due to delayed Enterprise Health sales, but improved margins in service and personal device growth partially offset losses.
Key Takeaways
Ekso Bionics saw a significant drop in revenue during Q2 2025, primarily from delayed Enterprise Health sales, but partially offset by increased Personal device sales and reduced service costs.
Revenue declined to $2.06 million from $4.95 million YoY.
Gross margin decreased to 40% from 53% YoY.
Net loss widened to $2.7 million compared to $2.4 million in Q2 2024.
Ekso Indego Personal sales grew more than 50% in the first half of 2025.
Forward Guidance
Ekso aims to recover in H2 2025 through delayed Enterprise Health sales and continued momentum in Personal Health devices, supported by new AI initiatives.
Positive Outlook
- Ekso Indego Personal devices grew >50% YoY in H1 2025
- Ekso Voice Agent launched as AI control solution for devices
- Joined NVIDIA Connect program for AI development
- eksoUniversity platform launched for physical therapist education
- Service margins improved due to cost reductions
Challenges Ahead
- Q2 revenue fell by more than 50% YoY
- Gross margin declined to 40%
- Enterprise Health sales faced delays
- Increased shipping and fixed costs impacted margins
- Net loss widened to $2.7 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...